BioCentury
ARTICLE | Company News

Medivir neurology news

June 29, 2015 7:00 AM UTC

Medivir said it will exit the neuropathic pain therapeutic area following adverse findings in non-clinical safety studies of MIV-247. Medivir has discontinued development of the cathepsin S inhibitor...